Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide - Scorecard - MDSpire
Advertisement
Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide
Clinical Scorecard: Evaluating Alcohol and Substance Use in Candidates for Bariatric Surgery: The Role of Self-Reported Data and Toxicology Assessments, Including Ethyl-Glucuronide
At a Glance
Category
Detail
Condition
Alcohol and substance use in bariatric surgery candidates
Key Mechanisms
Assessment of risky alcohol consumption and substance use via self-report questionnaires and urine toxicology including ethyl glucuronide (EtG) biomarker
Target Population
Candidates for primary bariatric surgery at a tertiary hospital obesity unit
Care Setting
Preoperative psychological evaluation in a tertiary hospital obesity unit
Key Highlights
Risky drinking defined as >2 standard drinks/day or >4 on a single occasion, increasing risk of alcohol use disorder (AUD).
Use of validated screening tools (AUDIT-C, ASSIST) combined with urine EtG and drug testing enhances detection of alcohol and substance use.
4% of candidates met criteria for alcohol abuse and 2% for dependence; 33% had a current Axis I psychiatric disorder, with major depressive disorder most common.
Guideline-Based Recommendations
Diagnosis
Include alcohol and substance use assessment in preoperative psychological evaluation for bariatric surgery candidates.
Use validated questionnaires such as AUDIT-C for risky alcohol use and ASSIST for substance involvement screening.
Employ objective biomarkers like urine ethyl glucuronide (EtG) to detect recent alcohol consumption up to 72 hours.
Screen for psychiatric comorbidities using structured interviews like the MINI.
Management
Identify and address risky drinking and substance use prior to bariatric surgery to optimize outcomes.
Consider psychopharmacological treatment needs as 32% of candidates were on antidepressants and 28% on benzodiazepines.
Provide targeted interventions for patients with diagnosed AUD or other substance use disorders.
Monitoring & Follow-up
Use urine toxicology including EtG and drug screening to monitor alcohol and substance use during preoperative assessment.
Regularly reassess alcohol and substance use patterns postoperatively due to increased risk of AUD development.
Risks
Risky alcohol use negatively impacts weight loss and nutritional status post-bariatric surgery.
Increased risk of developing alcohol use disorder after bariatric surgery in a subset of patients.
Undetected substance use may complicate surgical outcomes and postoperative care.
Patient & Prescribing Data
Bariatric surgery candidates with obesity and comorbid psychiatric conditions
High prevalence of psychopharmacological treatment: 32% antidepressants, 28% benzodiazepines, 17% opioids, 5% antipsychotics, indicating need for integrated psychiatric and substance use management.
Clinical Best Practices
Combine self-reported questionnaires with objective urine biomarkers (EtG) for comprehensive alcohol use assessment.
Screen for both alcohol and other substance use systematically in bariatric surgery candidates.
Incorporate psychiatric evaluation to identify comorbid mental health disorders influencing substance use.
Use hierarchical logistic regression to identify predictive factors for risky drinking to tailor interventions.
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
Researchers examine postdischarge pain management after elective colorectal surgery, focusing on how prescribing practices align with actual opioid use at home.
